Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | In-registry randomization as a cost-effective model for surgical trials

Thorsten Kühn, MD, PhD, Universitätsklinikum Ulm, Ulm, Germany, describes the rationale for conducting the AXSANA (NCT04373655) trial as a prospective cohort registry study, explaining that randomized surgical trials face significant funding challenges. This approach represents a solution to address remaining clinical questions, as all techniques employed are established rather than experimental. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, as I said, so for a final conclusion, it is certainly better to have randomized data. One reason why we conducted AXSANA as a prospective study or prospective cohort registry study was that it’s very difficult for surgical trials to get the funding for these trials. So this is very difficult. That’s why we started AXSANA as a prospective registry. However, within this registry where we have an established network with more than 300 sites, we have ethical approval...

Yeah, as I said, so for a final conclusion, it is certainly better to have randomized data. One reason why we conducted AXSANA as a prospective study or prospective cohort registry study was that it’s very difficult for surgical trials to get the funding for these trials. So this is very difficult. That’s why we started AXSANA as a prospective registry. However, within this registry where we have an established network with more than 300 sites, we have ethical approval. All techniques that are applied in the study are not experimental. So we can, within this cohort study, we can perform a randomization without additional costs. And this is a very elegant way to include a randomisation which is an in-registry randomization and then give answers and solve the remaining issues to compare sentinel-lymph node biopsy and TAD.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.